Key facts
- It has raised $10.0M; the latest was Seed Round ($10.0M) in Aug 2025.
- Notable investors include Plaisance Capital, Gaorong Ventures, Jifeng Ventures, Qiji Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ALLYRNA
- ·The full record, as it builds
Funding rounds
No funding rounds for ALLYRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ALLYRNA
Developer of RNA-based biopharmaceutical technologies intended to accelerate therapeutic innovation in precision medicine. The company offers proprietary molecular platforms, cross-border research capabilities and targeted delivery systems, enabling clinical research institutions, drug developers and healthcare providers to advance treatment efficacy and expand access to next-generation therapies.
- Sector
- Healthcare
- HQ
- Hong Kong, Hong Kong
- Founded
- 2025
- Ownership
- Privately Held (backing)
ALLYRNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ALLYRNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ALLYRNA in its N-PORT filings yet. We sweep new filings monthly.